3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Pancreatic Neoplasms
10
Breast Neoplasms
8
Colorectal Neoplasms
7
Prostatic Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
4
Melanoma
4
COVID-19
4
Multiple Myeloma
3
Lung Neoplasms
3
Colonic Neoplasms
3
Unspecified Adult Solid Tumor, Protocol Specific
2
Solid Tumor
2
Recurrence
2
Rectal Neoplasms
2
Ovarian Neoplasms
2
Neoplasms, Plasma Cell
2
Neoplasm Metastasis
2
Leukemia
2
Glioblastoma
2
Gastrointestinal Neoplasms
2
Carcinoma, Renal Cell
2
Adenocarcinoma of Lung
2
Adenocarcinoma
2
Urologic Diseases
1
Untreated Resectable Pancreatic Adenocarcinoma
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Resectable Localized Prostate Cancer
1
Refractory or Relapsed Solid Tumors
1
Interventions
Sirolimus
9
Everolimus
3
Imatinib Mesylate
2
temsirolimus
1
saracatinib
1
nintedanib
1
carbon-11 acetate
1
Valproic Acid
1
Urination
1
Sugars
1
Simvastatin
1
Resveratrol
1
Respiratory Function Tests
1
Phlebotomy
1
Loratadine
1
Letrozole
1
Immunoglobulin G
1
Hydroxychloroquine
1
Glutamine
1
Genetic Testing
1
Doxycycline
1
Disulfides
1
Cetuximab
1
Celecoxib
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphangioleiomyomatosis
×
Hydroxychloroquine
×
Clear all
NCT01687179
2018-10-11
SAIL
Brigham and Women's Hospital
Phase 1
Completed
14 enrolled
14 charts